Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human Study to Determine the Safety, Pharmacokinetics and Efficacy of KPG-121 When Administered With Enzalutamide, Abiraterone, or Apalutamide in Subjects With Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

NCT03569280 is registered in ClinicalTrials.gov with Kangpu Biopharmaceuticals, Ltd. as lead sponsor.

NCT NCT03569280
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03569280 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human Study to Determine the Safety, Pharmacokinetics and Efficacy of KPG-121 When Administered With Enzalutamide, Abiraterone, or Apalutamide in Subjects With Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Kangpu Biopharmaceuticals, Ltd.
Phase
Phase 1
Overall status
Completed
Start date
November 26, 2019
Completion date
June 15, 2023
Enrollment
16 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer